See what doctors and pharmacists say about their experiences with RELISTOR in clinical trials.
NOTE: In order to view these videos, you must be registered and signed in as a health care professional at Wyeth.com. If you are not yet registered, register now.
The clip below is a sample of the videos available once you sign in/register.
This video requires the latest version of Adobe Flash Player.
Indication
RELISTOR is indicated for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Use of RELISTOR beyond
4 months has not been studied.
Important Safety Information
- RELISTOR is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction
- If severe or persistent diarrhea occurs during treatment, advise patients to discontinue therapy with RELISTOR and consult their physician
- Use of RELISTOR has not been studied in patients with peritoneal catheters
- The most common adverse reactions reported with RELISTOR compared with placebo in clinical trials were abdominal pain (28.5% vs 9.8%), flatulence (13.3% vs. 5.7%), nausea (11.5% vs 4.9%), dizziness (7.3% vs 2.4%), and diarrhea (5.5% vs 2.4%)
Please see the full Prescribing Information.